microRNA-200c预测肺腺癌患者对吉非替尼的敏感性及其机制

Predictive value of microRNA-200c expression in patients with lung adenocarcinoma receiving gefitinib and its mechanisms

目的:探讨microRNA-200c的表达对肺腺癌患者吉非替尼敏感性的影响及其机制。方法:收集38例EGFR基因敏感突变且选用吉非替尼初治的肺腺癌患者外周血,采用real-time PCR法检测microRNA-200c的表达量,MSP法检测microRNA-200c启动区的甲基化状态。结果:对吉非替尼敏感的29例患者均存在microRNA-200c的相对高表达,其启动子区为非甲基化状态;耐药的9例患者存在microRNA-200c相对低表达,启动子区为甲基化状态。结论:肺腺癌患者microRNA-200c的表达与吉非替尼敏感性相关,作用机制可能为其启动子区的甲基化状态。

Objective：To explore the effect of microRNA - 200c expression on receiving gefitinib in patients with lung adenocarcinoma and its mechanisms. Methods：Peripheral blood in 38 patients with EGFR gene sensitive mutation and initial treatment options of gefitinib was used. The expression levels of microRNA - 200c were evaluated by real - time PCR. The methylation of microRNA - 200c promoter region was evaluated by methylation - specific PCR （MSP）. Results：Twenty nine patients who were sensitive to gefitinib highly expressed microRNA - 200c with promoter unmethylated,9 patients who were insensitive to gefitinib expressed low levels of microRNA - 200c with promoter methylated. Conclusion：microRNA - 200c expression in patients with lung adenocarcinoma has relation with the sensitivity to gefitinib. Its mechanisms may relate to methylation status of microRNA - 200c promoter region.